We developed an HPLC procedure using electrochemical detection for the quantitation of oxycodone and hydrocotarnine in cancer patients serum. An eluent of methanol:acetonitrile:5 mM pH 8 phosphate buffer (2:1:7) was used for the mobile phase. The calibration curve was linear in the range from 10 ng/mL to 100 ng/mL. The recovery of oxycodone and hydrocotarnine was 97.2% and 90.5%, respectively. The relative standard deviations within-runs and between-runs for the assay of oxycodone or hydrocotarnine were less than 4.8%. The method developed here was better than the method reported previously.
Oxycodone is a thebaine derivative with ∼0.5 -0.7 times the analgesic potency of morphine in humans. Oxycodone has been in clinical use since 1917 in Europe and America. Twelve-hour controlled-release oxycodone has been in clinical use since 1997 in America, and since 1998 in Germany. Although the injection formulation of oxycodone and hydrocotarnine has been in clinical use since 1926 in Japan, it was rarely used for the treatment of cancer pain, because morphine was mostly used.
Hydrocotarnine is a non-drug opium alkaloid thought to enhance the analgesic effect of opioids.
The detailed pharmacokinetics/pharmacodynamics is unclear; and how it should be used for patients with cancer has not been established.
Twelve-hour, controlled-release oxycodone has been in clinical use since 2003 in Japan, and the cases for which the injection formulation of oxycodone and hydrocotarnine are used are expected to increase.
We developed an HPLC procedure using electrochemical detection for the quantitation of oxycodone and hydrocotarnine in the serum of patients who used the injection formulation of oxycodone and hydrocotarnine appropriately.
Experimental

Reagents
Oxycodone (Lot. No. T2-00001) and hydrocotarnine (Lot. No. SBH002) were kindly supplied by Takeda Co. (Osaka, Japan). One percent Codeine (internal standard) was purchased from Takeda Co. (Osaka, Japan). The solvents to be used for the mobile phase were of chromatographic grade. All other chemicals were of special reagent grade.
Chromatography
Chromatograms were obtained using a PU-2080 pump (Nihon Bunko) equipped with an electrochemical detector, Coulochem II5200A and Model 5020 (MCMEDICAL). An XTerra ® RP18 column (5 µm, 4.6 mm × 50 mm i.d., Waters, Japan) at an ambient temperature (40˚C) was used to separate the oxycodone, hydrocotarnine, and codeine. The separation of the oxycodone, hydrocotarnine and codeine was achieved using an eluent of methanol:acetonitrile:5 mM pH 8 phosphate buffer (2:1:7).
The voltage of the working electrode of the electrochemical detector was set at 800 mV.
Sample treatment
Blood samples (2.0 mL) were immediately centrifuged at 3000 rpm for 10 min. To 1.0-mL serum sample (standard or unknown) was added 100 µL codeine (internal standard, 25 ng/mL), 0.5 mL 4 M NaOH, and 4 mL butyl chloride. The samples were then mixed for 15 min, centrifuged for 10 min at 3000 rpm, and the butyl chloride (top layer) was transferred to a clean glass tube. The remaining aqueous layer was extracted by another 4 mL butyl chloride using the same procedure. The combined butyl chloride extract was then evaporated. The dried residue was reconstituted in 200 µL mobile phase, and 40 µL solution was injected into the HPLC.
Determination of oxycodone and hydrocotarnine in patient serum
A patient with cancer pain hospitalized at Kitasato University Hospital was tested after obtaining the informed written consent 
Results and Discussion
Chromatographic separation and quantitative response
The mobile phases shown in Tables 1 and 2 were examined for the separation of oxycodone, hydrocotarnine, codeine and interference in serum. As a result, optimal separation on the chromatogram was obtained using a mobile phase of methanol:acetonitrile:5 mM pH 8 phosphate buffer (2:1:7). Figure 1 shows typical chromatograms obtained from the control serum and the patient serum. A linear-regression analysis of the standard curve from 10 ng/mL to 100 ng/mL yielded the following equation: y = 0.0479x -0.0613 (r = 0.999, oxycodone), y = 0.0296x -0.0014 (r = 0.998, hydrocotarnine). A good correlation was obtained between the ratio of the peak of oxycodone or hydrocotarnine to codeine and the concentration of oxycodone or hydrocotarnine in the serum. The lower limit of quantification was 0.5 ng/mL for oxycodone, and 0.6 ng/mL for hydrocotarnine (S/N = 2). The relative standard deviations within-runs (n = 10) and between-runs (n = 5) for the assay of oxycodone or hydrocotarnine were less than 4.8% (Table 3 ). The recovery of oxycodone and hydrocotarnine was 97.2% and 90.5%, respectively. The method developed here was better than the method reported previously. 1,2
Determination of oxycodone and hydrocotarnine in patient serum
The analytical method was applied to determine oxycodone 338 ANALYTICAL SCIENCES MARCH 2005, VOL. 21 and hydrocotarnine in patient serum. Figure 2 shows the time course of the oxycodone and hydrocotarnine concentration in the serum. 
